[Wiskott-Aldrich syndrome: recent progress in diagnosis and treatment].
Nonoyama
Shigeaki
S
D000818:Animals; D001565:Benzoates / Q000627:therapeutic use; D016026:Bone Marrow Transplantation; D003598:Cytoskeletal Proteins / Q000172:deficiency / Q000235:genetics / Q000502:physiology; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D006834:Hydrazines / Q000627:therapeutic use; D047908:Intracellular Signaling Peptides and Proteins / Q000172:deficiency / Q000235:genetics / Q000502:physiology; D009154:Mutation; D011720:Pyrazoles / Q000627:therapeutic use; D012720:Severity of Illness Index; D014923:Wiskott-Aldrich Syndrome / Q000175:diagnosis* / Q000235:genetics / Q000503:physiopathology / Q000628:therapy*; D051316:Wiskott-Aldrich Syndrome Protein / Q000235:genetics / Q000502:physiology
D001565:Benzoates; D003598:Cytoskeletal Proteins; D006834:Hydrazines; D047908:Intracellular Signaling Peptides and Proteins; D011720:Pyrazoles; C495767:WAS protein, human; C109903:WIPF1 protein, human; D051316:Wiskott-Aldrich Syndrome Protein; C520809:eltrombopag